Mode
Text Size
Log in / Sign up
N/A N=23 Randomized Single-blind Supportive Care

Standardized Patient-Centered Medication Review in Home Hospice

Hospices · Poly Pharmacy · Deprescriptions · Caregivers · Palliative Care

Enrolled (actual)
23
Serious AEs
0.0%
Results posted
May 2025
Primary outcome: Primary: Intervention Training Completion by Hospice Staff — 17; 0 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
NIA Medication Management - Active Comparator (Behavioral); STOPPFrail (Screening Tool of Older Persons Prescriptions) (Behavioral); "Discontinuing Medication Appropriately" and "Understanding the Art of Communication about Deprescribing" (Behavioral); "Key Approaches to Support Informal Family Caregivers in Managing Medications" (Behavioral)
Age
Older Adult · 65+ yrs
Sex
All
Sponsor
University of Massachusetts, Worcester
Primary completion
Dec 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Intervention Training Completion by Hospice Staff
17; 0
PRIMARY
Patient and Family Caregiver Eligibility Screens
77; 184
PRIMARY
Patient and Family Caregiver Enrollment
7; 15
PRIMARY
Completion of Primary Patient Outcome--Retention
7; 15
SECONDARY
Family Caregiver Medication Administration Hassle Scale
13.6; 31; 19.7; 37; 16.7; 36.1
SECONDARY
Medication Regimen Complexity Index
39; 23.5; 43.5; 31.0; 43.3; 32.5
SECONDARY
Potential Adverse Event
0; 0; 0; 0; 0; 0

Summary

This is a pilot cluster randomized trial that tests the effect of a novel intervention that trains hospice staff to 1. regularly review, simplify, and align patients' prescribed medications with their goals of care as their illness progresses, and 2. support family caregivers with education that empowers them to understand each medication's use, develop skills for safe administration, and 3. understand when stopping medications may be beneficial.

Eligibility Criteria

Inclusion Criteria

Patient - Newly admitted home hospice enrollees, aged ≥65 years old with:

  • 1. advanced life-limiting illness;
  • 2. an estimated life expectancy of >1 month;
  • 3. recent functional status decline (defined as change in Karnofsky Performance Status [KPS] to < 80% in prior 3 months);
  • 4. polypharmacy (defined as ≥ 5 regularly scheduled medications [excluding antimicrobials]);
  • 5. cognitive ability to provide informed consent based on a Short Portable Mental Status Questionnaire (SPMSQ) score ≥6 OR, with a legally authorized representative who is willing and able to provide proxy consent.

Family ("any relative, partner, friend or neighbor who has a significant personal relationship with, and provides a broad range of assistance) Caregiver -

  • self-identification as "usually" or "always" providing care to the eligible patient;
  • English-speaking;
  • telephone access; and
  • cognitive ability to participate.

Exclusion Criteria

Patient:

  • Imminent death;
  • pain crisis;
  • no family caregiver or health care proxy

Family Caregiver:

  • no telephone access;
  • cognitive impairment.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03972163). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search